Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Verzenios 50 mg film-coated tablets, TEMOZOLOMIDE , IRINOTECAN , Abemaciclib, Abemaciclib
Eli Lilly Co.
Ewings Sarcoma
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Azacitidin STADA 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Azacitidine Mylan 25 mg/mL powder for suspension for injection, Azacitidine Mylan 25 mg/mL powder for suspension for injection, pevonedistat hydrochloride, Venclyxto 100 mg film-coated tablets
Takeda
Acute Myeloid Leukemia
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets
Lacuna Pharma Pty Ltd
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, PIVEKIMAB SUNIRINE, Venclyxto 100 mg film-coated tablets
AbbVie Deutschland GmbH & Co. KG
CD123 positive Acute Myeloid Leukemia
1 trial -
Vizimpro 15 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets
Fondazione Telethon ETS
Advanced or metastatic untreated EGFR mutation positive NSCLC
1 trial -
Xarelto 2.5 mg film-coated tablets
Tour Hekla
Chronic hemodialysis
1 trial -
Xeloda 150 mg film-coated tablets, ELOXATINE 5 mg/ml, solution Γ diluer pour perfusion, Folinic acid (as calcium folinate) 10Β mg/ml solution for injection/infusion, ELVORINE 100 mg/10 mL, solution injectable, FLUOROURACILE TEVA 1000 mg/20 ml, solution Γ diluer pour perfusion
CERO THERAPEUTICS HOLDINGS, INC.
colon cancer
1 trial -
Xeloda 150 mg film-coated tablets, Folinic acid (as calcium folinate) 10Β mg/ml solution for injection/infusion, ELOXATINE 5 mg/ml, solution Γ diluer pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, FLUOROURACILE TEVA 1000 mg/20 ml, solution Γ diluer pour perfusion
CERO THERAPEUTICS HOLDINGS, INC.
metastatic colorectal adenocarcinoma
1 trial -
Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Paclitaxel 6 mg/mL concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, GEMZAR 200 mg, poudre pour solution pour perfusion, HALAVEN 0.44 mg/ml solution for injection, Vinorelbine 10 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion, evorpacept, HALAVEN 0.44 mg/ml solution for injection
ALX ONCOLOGY HOLDINGS INC
Breast Cancer
1 trial -
Xospata 40 mg film-coated tablets
Fondazione Telethon ETS
newly diagnosed non-M3 FLT3-positive acute myeloid leukemia
1 trial -
Xospata 40 mg film-coated tablets
Wuhan Createrna Science and Technology Co., Ltd
Acute myeloid leukaemia, Acute myeloid leukaemia
1 trial -
Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets
GlaxoSmithKline
Neoplasms
1 trial -
Zejula 100 mg hard capsules, Zejula 100 mg film-coated tablets, JEMPERLI 500 mg concentrate for solution for infusion
Ningbo Cancer Hospital
metastatic or recurrent endometrial or ovarian carcinosarcoma
1 trial -
Zelboraf 240 mg film-coated tablets
Ningbo Cancer Hospital
Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment
1 trial -
experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo
Universal Integrated
Anovulatory Infertility
1 trial -
osimertinib mesylate tablets and anlotinib hydrochloride capsules
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
tamuzimod, tamuzimod, tamuzimod, VTX002 placebo film-coated tablets matching VTX002, tamuzimod
Lacuna Pharma Pty Ltd
Moderately to Severely Active Ulcerative Colitis
1 trial -
tovinontrine-matching placebo, immediate-release tablet, Tovinontrine
Lacuna Pharma Pty Ltd
chronic heart failure
1 trial -
100 mg Resmetirom Tablet
Madrigal Pharmaceuticals EU Limited
Renal Impairment
1 trial -
300 mg LX4211 (150 mg tablets)
LEXICON PHARMACEUTICALS, INC.
Type 2 Diabetes Mellitus
1 trial -
45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)
Teva Pharma GmbH
Drug Abuse
1 trial -
5 mg/500 mg Glipizide Metformin Hydrochloride Tablets
Teva Pharma GmbH
Healthy
1 trial -
5 mg/500 mg METAGLIPβ’ Tablets
Teva Pharma GmbH
Healthy
1 trial -
90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).
Teva Pharma GmbH
Pain
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources